Genesis IBRC India Ltd Stock Price Today (NSE: GENESIS)
Fundamental Score
Genesis IBRC India Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Genesis IBRC India Ltd share price today is ₹116.90, up +0.00% on NSE/BSE as of 1 August 2026. Genesis IBRC India Ltd (GENESIS) is a Small-cap company in the Biotechnology sector with a market capitalisation of ₹475.35 (Cr). The 52-week high for GENESIS share price is ₹184.90 and the 52-week low is ₹31.31. The company has a Return on Equity (ROE) of -2.92% and a debt-to-equity ratio of 0.00.
Genesis IBRC India Ltd Share Price Chart — NSE/BSE Historical Performance
Genesis IBRC India Ltd share price chart: -0.51% return over the past month. 52-week high ₹184.90, 52-week low ₹31.31.
Genesis IBRC India Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹116.90 | ₹116.90 | ₹116.90 | ₹116.90 | 0.00 (Cr) | |
| ₹116.90 | ₹116.90 | ₹116.90 | ₹116.90 | 0.00 (Cr) | |
| ₹116.90 | ₹116.90 | ₹116.90 | ₹116.90 | 0.00 (Cr) | |
| ₹116.90 | ₹116.90 | ₹116.90 | ₹116.90 | 0.00 (Cr) | |
| ₹116.90 | ₹116.90 | ₹116.90 | ₹116.90 | 0.00 (Cr) | |
| ₹116.90 | ₹116.90 | ₹116.90 | ₹116.90 | 0.00 (Cr) | |
| ₹116.90 | ₹116.90 | ₹116.90 | ₹116.90 | 0.00 (Cr) | |
| ₹116.90 | ₹116.90 | ₹116.90 | ₹116.90 | 0.00 (Cr) | |
| ₹116.90 | ₹116.90 | ₹116.90 | ₹116.90 | 0.00 (Cr) | |
| ₹116.90 | ₹116.90 | ₹116.90 | ₹116.90 | 0.00 (Cr) |
Genesis IBRC India Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹116.90 | ₹116.90 | ₹116.90 | ₹116.90 | +0.00% | |
| ₹117.00 | ₹130.10 | ₹116.90 | ₹116.90 | -0.09% | |
| ₹98.98 | ₹118.08 | ₹73.90 | ₹111.95 | +13.10% | |
| ₹75.45 | ₹108.45 | ₹75.45 | ₹98.98 | +31.19% | |
| ₹99.00 | ₹104.00 | ₹59.43 | ₹75.45 | -23.79% | |
| ₹85.30 | ₹96.21 | ₹69.35 | ₹89.90 | +5.39% | |
| ₹150.75 | ₹150.75 | ₹80.75 | ₹85.30 | -43.42% | |
| ₹167.55 | ₹184.90 | ₹143.20 | ₹143.60 | -14.29% | |
| ₹75.22 | ₹164.30 | ₹75.22 | ₹164.30 | +118.43% | |
| ₹38.04 | ₹71.64 | ₹38.04 | ₹71.64 | +88.33% | |
| ₹31.31 | ₹38.04 | ₹31.31 | ₹38.04 | +21.49% |
AI Research Briefing
Powered by Gemini · 2026-08-01
An operational shell with zero revenue generation masquerading as a micro-cap momentum vehicle.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major commercial or operational catalysts found after live search. The corporate machinery remains dormant, with attention restricted to administrative housekeeping including the appointment of Garima Garg as Compliance Officer effective April 2026 and shifting books of accounts maintenance to a Mumbai office location. Zero revenue generating announcements or institutional updates.
CORE STORY (THE REAL GAME)
Shell company trading vehicle masquerading as a legacy biotech name, driven entirely by micro-cap liquidity loops and promoter holding consolidation rather than commercial operations.
- Promoter group holding tightly consolidated at 74.17%
- Complete lack of operational news or revenue generation
- Extreme vulnerability to sudden lower circuit lock-ins
- Sudden operator-driven volume spikes
- Announcement of a reverse merger or shell takeover
- Wholesale exit of micro-cap retail participants
- Zero active business operations and negative net worth expansion
- Absolute liquidity risk as a micro SME cap trading trap
- No institutional sponsorship with FII and DII holding at absolute zero
Promoter holding stands at 74.17% following past off-market structural transfers, while FII and DII participation remains completely non-existent at 0.0%
Domestic micro-cap liquidity is tightening as regulatory scrutiny on shell structures intensifies.
No major news found after live search.
no
Dormant operations will likely force the stock back toward its lower historical valuation bands as speculative interest dries up. Avoid any tactical deployment of capital.
Primary Thesis Risk
Complete absence of underlying business operations combined with zero exit liquidity.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Genesis IBRC India Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Genesis IBRC India Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GENESIS across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (74.17%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (-2.92%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-2.92%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-2400.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (-21.39% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Genesis IBRC India Ltd vs Biotechnology Peers
Peer Comparison - Biotechnology
Compare Genesis IBRC India Ltd with 4 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Genesis IBRC India LtdGenesis IBRC In...Selected✓ GENESIS • 514336 | 9/100 | ₹116.90₹117 | ₹475.35₹475.35 | — — | -2.92%Poor -2.92% Poor | -2.92%Poor -2.92% Poor | 0.00Excellent 0.0 Excellent | — — | — — | 0.00% |
Anthem Biosciences LimitedAnthem Bioscien... ANTHEM • 544449 | 65.9/100 | ₹809.20₹809 | ₹42276.24₹42276.24 | 69.60Average 69.6 Average | 22.28%Excellent 22.28% Excellent | 30.37%Excellent 30.37% Excellent | 0.02Excellent 0.0 Excellent | 17.48%Excellent 17.48% Excellent | 14.00%Good 14.00% Good | 0.27% |
Advanced Enzyme Technologies LtdAdvanced Enzyme... ADVENZYMES • 540025 | 63.4/100 | ₹315.10₹315 | ₹3666.09₹3666.09 | 23.65Average 23.6 Average | 10.16%Average 10.16% Average | 13.96%Average 13.96% Average | 0.02Excellent 0.0 Excellent | 1.25%Average 1.25% Average | 8.24%Good 8.24% Good | 1.63% |
Vivo Bio Tech LtdVivo Bio Tech L... VIVOBIOT • 511509 | 8.1/100 | ₹21.42₹21 | ₹51.86₹51.86 | — — | -2.00%Poor -2.00% Poor | 7.29%Poor 7.29% Poor | 0.72Good 0.7 Good | — — | 0.59%Average 0.59% Average | 0.00% |
Genomic Valley Biotech LtdGenomic Valley ... GVBL • 539206 | 36.4/100 | ₹27.55₹28 | ₹8.73₹8.73 | 290.85Average 290.9 Average | 0.77%Poor 0.77% Poor | 1.02%Poor 1.02% Poor | 0.00Excellent 0.0 Excellent | 15.48%Excellent 15.48% Excellent | 5.15%Good 5.15% Good | 0.00% |
Top Biotechnology Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
Genesis IBRC India Ltd Quarterly Performance
Latest quarterly metrics for GENESIS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-2400.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Genesis IBRC India Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for GENESIS — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Genesis IBRC India Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Genesis IBRC India Ltd (GENESIS) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Genesis IBRC India Ltd
About GENESIS (Genesis IBRC India Ltd)
Genesis IBRC India Ltd is a biotechnology company rooted in Eluru, India, with a history of developing and commercializing pro-biotic solutions. Originally incorporated in 1992 and... formerly known as SSK Lifestyles Limited, the company initially focused on leveraging the power of beneficial microorganisms to enhance productivity and sustainability across diverse agricultural sectors. Their early endeavors centered around creating pro-biotic formulations specifically tailored for aquaculture, agriculture, poultry, and animal husbandry. These products aimed to improve animal health, enhance crop yields, and promote environmentally sound practices within these industries. While the company's initial vision centered around these applications, its current operational status reflects a period of transition. Though Genesis IBRC India Ltd once actively manufactured and marketed pro-biotic products, its current activities are not substantial, according to recent reports. The shift likely reflects the dynamic nature of the biotechnology market and the challenges inherent in scaling and sustaining operations within the agricultural sector. A variety of factors could contribute to this change, including evolving market demands, shifts in regulatory landscapes, and the inherent complexities of developing and distributing effective pro-biotic solutions. The company's journey exemplifies the often-unpredictable path of biotechnology ventures, where innovation and market acceptance must align to ensure long-term viability. Despite its current status, the historical focus of Genesis IBRC India Ltd on pro-biotic solutions reveals a commitment to harnessing the potential of biological systems for practical applications. The company's initial efforts in developing products for aquaculture, agriculture, poultry, and animal husbandry demonstrate a clear understanding of the interconnectedness of these sectors and the potential for biotechnology to contribute to sustainable and efficient resource management. Whether the company will refocus and redirect its strategy to capitalize on biotechnology opportunities remains to be seen; however, its past endeavors highlight its initial aspirations within the Indian biotechnology landscape.
Company Details
Key Leadership
GENESIS Share Price: Frequently Asked Questions
What is the current share price of Genesis IBRC India Ltd?
Genesis IBRC India Ltd (GENESIS) trades at ₹116.90 on NSE and BSE. Market cap ₹475.35 (Cr). Educational data only.
What is the P/E ratio of Genesis IBRC India Ltd?
Genesis IBRC India Ltd has a P/E of N/Ax vs industry average 46.63x.
What is the Bull Run score for Genesis IBRC India Ltd?
Genesis IBRC India Ltd has a Bull Run score of 9/100 based on 25+ financial parameters.
Does Genesis IBRC India Ltd pay dividends?
Genesis IBRC India Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Genesis IBRC India Ltd?
Genesis IBRC India Ltd has ROE of -2.92%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Genesis IBRC India Ltd?
Genesis IBRC India Ltd has debt-to-equity of 0.00.
Is Genesis IBRC India Ltd a good investment?
Bull Run gives Genesis IBRC India Ltd a score of 9/100. This is not investment advice — consult a SEBI-registered advisor.